Browsing by author "Grob, Jean-Jacques"
Sort by:
Title A-Z
-
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.
Atkinson, Victoria; Robert, Caroline; Grob, Jean-Jacques; Gogas, Helen; Dutriaux, Caroline; Demidov, Lev V.; Gupta, Avinash; Menzies, Alexander M.; Ryll, Bettina; Miranda, Flora; Banerjee, Hiya; Lau, Mike R.; Del Vecchio, MichelePublished 2021Background: The long-term benefit of adjuvant dab + tram in pts with resected stage III BRAF V600E/K–mutant melanoma was demonstrated in COMBI-AD where AEs led to permanent discontinuation of dab + tram in 26% of pts, most ...Article -
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Luke, Jason J; Rutkowski, Piotr; Queirolo, Paola; Del Vecchio, Michele; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; de la Cruz Merino, Luis; Khattak, Muhammad A; Schadendorf, Dirk; Long, Georgina V; Ascierto, Paolo A; Mandala, Mario; De Galitiis, Federica; Haydon, Andrew; Dummer, Reinhard; Grob, Jean-Jacques; Robert, Caroline; Carlino, Matteo S; Mohr, Peter; Poklepovic, Andrew; Sondak, Vernon K; Scolyer, Richard A; Kirkwood, John M; Chen, Ke; Diede, Scott J; Ahsan, Sama; Ibrahim, Nageatte; Eggermont, Alexander M M; Investigators, KEYNOTE-716Published 2022Background Pembrolizumab prolongs progression-free and overall survival among patients with advanced melanoma and recurrence-free survival in resected stage III disease. KEYNOTE-716 assessed pembrolizumab as adjuvant ...Article
Sort by:
Title A-Z